(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.49%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.66%.
Cocrystal Pharma's earnings in 2026 is -$9,938,000.On average, 4 Wall Street analysts forecast COCP's earnings for 2026 to be -$12,476,775, with the lowest COCP earnings forecast at -$12,459,438, and the highest COCP earnings forecast at -$12,338,080. On average, 3 Wall Street analysts forecast COCP's earnings for 2027 to be -$11,396,109, with the lowest COCP earnings forecast at -$10,949,203, and the highest COCP earnings forecast at -$11,731,289.
In 2028, COCP is forecast to generate -$12,378,532 in earnings, with the lowest earnings forecast at -$11,893,100 and the highest earnings forecast at -$12,742,607.